Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase …

B Wacker, T Nagrani, J Weinberg, K Witt, G Clark… - Clinical Cancer …, 2007 - AACR
Purpose: Data from two large phase III studies were analyzed to characterize the correlation
between the occurrence of rash during treatment with the epidermal growth factor receptor …
被引用次数：490 相关文章

[引用][C] Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large …

B WACKER, T NAGRANI, J WEINBERG… - Clinical cancer …, 2007 - pascal-francis.inist.fr
Correlation between development of rash and efficacy in patients treated with the epidermal
growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies CNRS …

[引用][C] Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large …

B WACKER - Clin Cancer Res, 2007 - cir.nii.ac.jp
Correlation between development of rash and efficacy in patients treated with the epidermal
growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies | CiNii …

Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase …

B Wacker, T Nagrani, J Weinberg, K Witt… - … Cancer Research: an …, 2007 - europepmc.org
Correlation between development of rash and efficacy in patients treated with the epidermal
growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. - Abstract …

Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase …

B Wacker, T Nagrani, J Weinberg… - … : an official journal …, 2007 - pubmed.ncbi.nlm.nih.gov
Purpose Data from two large phase III studies were analyzed to characterize the correlation
between the occurrence of rash during treatment with the epidermal growth factor receptor …

[引用][C] Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large …

B WACKER - Clinical Cancer Research, 2007 - cir.nii.ac.jp
Correlation between development of rash and efficacy in patients treated with the epidermal
growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies | CiNii …

[引用][C] Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large …

B WACKER, T NAGRANI… - Clinical …, 2007 - American Association for Cancer …